## Inovio and Regeneron announce a clinical study for a immuno-oncology trial

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced a clinical study agreement for a phase 1b/2a immuno-oncology trial.

The study will be conducted by Inovio in patients with newly diagnosed glioblastoma multiforme (GBM) and will evaluate Regeneron's PD-1 inhibitor, REGN2810, in combination with Inovio's INO-5401 T cell activating immunotherapy encoding multiple antigens and INO-9012, an immune activator encoding IL-12.



too 1h/Za clinical trial will combine Repenseum PD-1 inhibitor MERZESS and Inovin's T cell thirder IND-5881 and immune activator IND-5882 i brain cancer The control of the co and the resident and extension the authority of the control of the The state of the s The control of the co